• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Ampyra

Merz Therapeutics Merz CEO Stefan Knig
Pharma

Merz to expand and hunt for more deals after closing Inbrija buy

Equipped with two approved meds from Acorda Therapeutics, Germany’s Merz Therapeutics is kicking its specialty neurology ambitions into high gear.
Fraiser Kansteiner Jul 11, 2024 4:08pm
Acorda Therapeutics

Biogen returns ex-U.S. rights of MS drug Fampyra to Acorda

Jan 11, 2024 1:15pm
Acorda Therapeutics

Slow Inbrija launch forces Acorda to slash $800M sales hopes

Feb 13, 2020 10:52am
Acorda

Acorda's sales team switches gears to promote Inbrija

Jan 15, 2019 11:20am
detour

Acorda's much-needed Inbrija hits a snag at the FDA

Sep 13, 2018 11:20am
Gavel court room lawsuit judge

Acorda desperately needs Inbrija nod after appeals loss

Sep 11, 2018 11:54am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings